Search clinical trials for: EGFR Sensitizing Mutation

Total 4317 results

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Yonsei University

Not yet recruiting

Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib (LUCAS)

Non-small Cell Lung Cancer

Korea, Republic of
Jiangsu Hansoh Pharmaceutical Co., Ltd.

Recruiting

Aumolertinib With or Without Chemotherapy as 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Sun Yat-sen University

Recruiting

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

Non-small Cell Lung Cancer (NSCLC) | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation | Somatic Mutation | Germline Mutations

China
Arcus Biosciences, Inc.
Gilead Sciences

Active, not recruiting

A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer (ARC-4)

Non Small Cell Lung Cancer | Nonsquamous Nonsmall Cell Neoplasm of Lung | Non Small Cell Lung Cancer Metastatic | Sensitizing EGFR Gene Mutation

United States, Korea, Republic of, Singapore, Taiwan
Yuhan Corporation

Active, not recruiting

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Non-Small Cell Lung Cancer

Hungary, Korea, Republic of, Australia, Taiwan, Serbia, Singapore, Thailand, Philippines, Turkey, Malaysia, Russian Federation, Greece, Ukraine
Yuhan Corporation

Completed

Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC

Non-small Cell Lung Cancer
Memorial Sloan Kettering Cancer Center

Completed

Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations

Oligometastatic Lung Adenocarcinoma

United States
SciClone Pharmaceuticals

Unknown

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

EGFR Mutation Positive Non Small Cell Lung Cancer

Italy
First People's Hospital of Hangzhou

Unknown

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Lung Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer
GenoSaber
Sun Yat-sen University; Shanghai Chest Hospital; Shanghai Pulmonary Hospital,...

Unknown

Human EGFR Mutations Quantitative Detection Kit (Real-time Fluorescent PCR Method)

Non Small Cell Lung Cancer | EGFR-TKI Resistant Mutation | EGFR-TKI Sensitizing Mutation
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC

Non Small Cell Lung Cancer | Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV
AstraZeneca
Daiichi Sankyo

Not yet recruiting

A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung15)

Metastatic Non-small Cell Lung Cancer
Shanghai JMT-Bio Inc.

Not yet recruiting

JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations

Local Advanced or Metastatic NSCLC
Bayer

Recruiting

A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
AstraZeneca

Not yet recruiting

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC (FOREFRONT)

Neoplasms | Respiratory Tract Diseases | Lung Diseases | Neoplasms by Site | Carcinoma, Non-Small-Cell Lung | Lung Neoplasms | Respiratory Tract Neoplasms | Thoracic Neoplasms | Carcinoma, Bronchogenic | Bronchial Neoplasms

China
National Cancer Center, China

Not yet recruiting

A Study With BPI-1178 and Osimertinib in Advanced Non-small Cell Lung Cancer Patients With EGFR Mutations (EGFR)

NSCLC
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial

Non-small Cell Lung Cancer | EGFR Activating Mutation | EGFR-TKI Resistant Mutation | Cell Cycle Deregulation

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW (WUKONG-32-RW)

Non-small Cell Lung Cancer

China
Tang-Du Hospital

Recruiting

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

EGF-R Positive Non-Small Cell Lung Cancer | CNS Metastases

China
Hunan Province Tumor Hospital

Not yet recruiting

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC (WUKONG-32)

Non-Small Cell Lung Cancer

China
Bayer

Recruiting

A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United States
AstraZeneca
Daiichi Sankyo

Recruiting

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer (TROPION-Lung14)

Non-small Cell Lung Cancer

Australia, China, Korea, Republic of, Taiwan
Bayer

Recruiting

A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants

Healthy Volunteers | Advanced Non-small Cell Lung Cancer | EGFR Mutation | HER2 Mutation

United Kingdom
Fudan University

Not yet recruiting

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Lung Cancer | Minimal Residual Disease | EGFR Gene Mutation
Suzhou Genhouse Bio Co., Ltd.

Recruiting

A Phase Ib/II Clinical Study of GH21 Capsules Combined With Osimertinib Mesylate Tablets in Patients With NSCLC

Non-Small Cell Lung Cancer With EGFR Mutation

China
Guangdong Provincial People's Hospital

Recruiting

Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC (NEOVADE)

Non Small Cell Lung Cancer | EGFR Gene Mutation

China
Dizal Pharmaceuticals

Recruiting

A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)

Non-small Cell Lung Cancer

China
National Taiwan University Hospital

Recruiting

Applying Mobile Healthcare Education to Improve Cutaneous Self-care Capability

Cancer | Drug-Related Side Effects and Adverse Reactions | Cancer, Treatment-Related | EGFR Gene Mutation

Taiwan
Dizal Pharmaceuticals

Recruiting

DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)

Non-small Cell Lung Cancer

China
Ruijin Hospital
Guangdong Provincial People's Hospital

Not yet recruiting

Neoadjuvant Toripalimab for Clinically Stage II-IIIB Resectable Non-small Cell Lung Cancer With EGFR Mutation and PD-L1 Positive Expression (TOPLINE)

Carcinoma, Non-Small-Cell Lung

China
Groupe Français de Pneumo-Cancérologie

Recruiting

Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion (RESAMEX)

Non-small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

France
Instituto Nacional de Cancerologia de Mexico

Recruiting

Nitroglycerin Plus Radiotherapy Versus Conventional Radiotherapy in Patients With Lung Cancer.

Non-small Cell Lung Cancer | Brain Metastases | EGFR Gene Mutation

Mexico
Fondazione Policlinico Universitario Agostino Gemelli...

Recruiting

Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) (GALILEO)

NSCLC Stage IV | ALK Gene Mutation | ALK Sensitizing Mutation

Italy
City Clinical Oncology Hospital No 1
Atlas Biomed; N.N. Blokhin National Medical Research Center of Oncology; Moscow...

Recruiting

Other Oncogene Mutations for Anti-EGFR Efficacy in Patients With Left-sided RAS-wild Type Metastatic Colorectal Cancer (CRC01)

Colorectal Neoplasms | Chemotherapy Effect | Molecular Sequence Variation

Russian Federation
The Netherlands Cancer Institute
Daiichi Sankyo, Inc.

Not yet recruiting

Whole Body HER3 Quantification With Radiolabelled Patritumab Deruxtecan (HER3-DXd) PET/CT

EGFR Gene Mutation | Non-Small Cell Lung Carcinoma | Advanced Non-Small Cell Squamous Lung Cancer
Radiotherapy Oncology Centre "Santa Maria" Hospital
Paola Anselmo,MD; Michelina Casale,PhD; Fabio Trippa,MD

Recruiting

Stereotactic Ablative Radiotherapy in Synchronous and Metachronous Oligo-Metastatic Non Small Cell Lung Cancer (STARTNEWERA-OM)

NSCLC | Non Small Cell Lung Cancer | EGF-R Positive Non-Small Cell Lung Cancer | Non Small Cell Lung Cancer Metastatic | NSCLC Stage IV | Oligometastatic Disease | Non-Small Cell Squamous Lung Cancer | Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor | Non-Small Cell Adenocarcinoma and other conditions

Italy
AstraZeneca

Recruiting

To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations (NEOLA)

Lung Cancer

Spain, Vietnam, China, India, Taiwan, Thailand, Israel, Turkey, United States, Korea, Republic of
Juan LI, MD

Recruiting

To Assess the Efficacy and Safety of Furmonertinib in Patients With Epidermal Growth Factor Receptor 20ins Mutation Positive Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy

Non Small Cell Lung Cancer | EGFR Exon 20 Insertion Mutation

China
Hideho Okada, MD, PhD
National Cancer Institute (NCI); California Institute for Regenerative Medicine...

Recruiting

Anti-EGFRvIII synNotch Receptor Induced Anti-EphA2/IL-13Ralpha2 CAR (E-SYNC) T Cells

Glioblastoma | Recurrent Glioblastoma | EGFR Gene Mutation | MGMT-Unmethylated Glioblastoma

United States
Cancer Institute and Hospital, Chinese Academy...

Not yet recruiting

RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations

Non Small Cell Lung Cancer | ERBB2 Mutation-Related Tumors | Disitamab Vedotin | ERBB2 Gene Duplication
Peking Union Medical College Hospital

Not yet recruiting

A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.

Non Small Cell Lung Cancer | Immune Checkpoint Inhibitor | EGFR Exon 21 Mutation

China
Daping Hospital and the Research Institute of Surgery...

Not yet recruiting

The Efficacy of Double-dose Furmonertinib in the Treatment of Patients With Slow Osimertinib-resistant NSCLC

Non Small Cell Lung Cancer | EGFR Gene Mutation | Non-small Cell Lung Cancer Stage IV | Non Small Cell Lung Cancer Stage IIIA
Kunming Medical University

Recruiting

A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation

Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Efficacy and Safety of Neoantigen Peptide Vaccine in the Treatment of Advanced NSCLC Progressed After EGFR-TKI Treatment

NSCLC | EGFR Gene Mutation

China
Merck Sharp & Dohme LLC

Recruiting

Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)

Non-small Cell Lung Cancer (NSCLC)

China, Taiwan, United States, Australia, Israel, Hong Kong, Chile, Korea, Republic of, Canada, Malaysia, Thailand
China Medical University Hospital

Not yet recruiting

Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients

Non-small Cell Lung Cancer | EGFR Gene Mutation | EGFR-TKI Resistant Mutation
National University Hospital, Singapore

Recruiting

Study of EGFR TKI in Patients With Advanced NSCLC Harbouring EGFR Mutations

NSCLC

Singapore
Intergroupe Francophone de Cancerologie Thoracique

Recruiting

A Prospective Cohort Study to Evaluate Molecular pRognostic Factors and Resistance Mechanisms to Osimertinib in Adjuvant Treatment of Completely Resected pIB-IIIA Non-small Cell Lung Carcinoma With Common EGFR Mutations (L858R and Del19) (ROSIE)

Non Small Cell Lung Cancer | EGFR Activating Mutation | EGFR L858R | EGFR DEL19

France
Haisco Pharmaceutical Group Co., Ltd.

Recruiting

Phase I Study of HSK40118 in NSCLC Patients With EGFR Mutation

NSCLC

China

Search clinical trials for: EGFR Sensitizing Mutation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations